Anzeige
Meldung des Tages: Neue Bohrungen könnten die Story dieser Kupfer-Aktie komplett verändern

Atossa Therapeutics News

Aktie
WKN:  A41ZVB ISIN:  US04962H7044 US-Symbol:  ATOS
5,41 $
+0,08 $
+1,50%
4,6623 € 14:52:07 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

Atossa Therapeutics News

06.10.25 - PR Newswire
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-​Enabling Activities PR Newswire
01.10.25 - PR Newswire
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones PR Newswire
08.09.25 - PR Newswire
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction PR Newswire
28.08.25 - PR Newswire
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference PR Newswire
20.08.25 - PR Newswire
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-​Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer PR Newswire
12.08.25 - PR Newswire
Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire
29.07.25 - PR Newswire
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer PR Newswire
02.06.25 - PR Newswire
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference PR Newswire
14.05.25 - PR Newswire
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen PR Newswire
13.05.25 - PR Newswire
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire

Newssuche

Videos

newspaper
19.03.26
COUNTER HUNTER Strategie Einführung
Live-​Seminar am 29.3. ab 14 Uhr! Wie immer wird die Schulung auch aufgezeichnet und allen ... Mehr »